Correo Electrónico
DNINFOA - SIA
Bibliotecas
Convocatorias
Identidad U.N.
Publicado
Anticuerpos neutralizantes contra el virus de la fiebre amarilla 17 D en colombianos vacunados y no vacunados con inmunidad a dengue
Yellow fever virus 17D neutralising antibodies in vaccinated colombian people and unvaccinated ones having immunity against dengue
Palabras clave:
Fiebre amarilla, flavivirus, vacuna contra la fiebre amarilla, pruebas de neutralización (es)Yellow fever, flavivirus, yellow fever vaccine, neutralisation test (en)
Descargas
Objetivo. Determinar la frecuencia de título protector de anticuerpos neutralizantes contra el virus de la fiebre amarilla (AN-VFA a título >1:10) en colombianos vacunados con la cepa 17 D y conocer la magnitud de neutralización del VFA por anticuerpos contra dengue.
Metodología. Se colectó suero de 100 individuos con vacuna documentada por carné y de 116 residentes en municipios de Norte de Santander afectados por el brote en 2002-2003, quienes informaron haber sido vacunados. Se incluyeron sueros de individuos no vacunados con (n=61) y sin (n=16) anticuerpos contra dengue. Todos los sueros se analizaron por la prueba de neutralización para VFA por 75 % de reducción de placa.
Resultados. AN-VFA a título >1:10 se encontraron en 90 % de vacunados con carné y sin variación aparente en relación con edad. Al contrario, hubo correlación entre disminución de la frecuencia de título protector de anticuerpos e incremento del tiempo de inmunización (r=0,95; p=0,04). En residentes de Norte de Santander, AN-VFA a título >1:10 se encontraron en 92,6 % adultos y 69 % niños. El VFA fue neutralizado (52 -100 %) por sueros de inmunes a dengue más eficientemente que por sueros de no inmunes (p<0.001).
Conclusiones. Vacunados con el virus 17 D podrían no estar protegidos contra fiebre amarilla: hasta 31 % niños y 10 % adultos. Anticuerpos contra dengue inhibieron el VFA y su significancia en términos de protección contra fiebre amarilla deberá ser investigada.
Objective. Determining the frequency of yellow fever seroprotective antibody neutralising titres (YF-NT >1:10) in Colombians vaccinated with the 17 D virus and ascertaining the extent to which YF virus can be neutralised by dengue antibodies.
Materials and Methods. Serum samples were taken from 100 subjects who showed their vaccination record and from 116 residents in municipalities (Norte de Santander) affected by a wild YF outbreak in 2002-2003 who were reported to have been YF vaccinated. Sera from individuals with (n=61) and without (n=16) dengue antibodies who had never been YF vaccinated were included. All the sera were tested by 75 % YF plaque-reduction neutralization test.
Results. YF-NT titres >1:10 were founded in 90 % of subjects with vaccination recorded with minors variations in relation to age. In contrast, there was correlation between decrease of seroprotective YF-NT titres frequency and increase of immunization time (r=0.95; p=0.04). In residents in YF endemic area, YF-NT titres > 1.10 were founded in 92,6 % adults and 69 % children. YF 17 D virus was neutralized (52-100 %) by dengue sera more efficiently than non-dengue immune sera (p<0.001).
Conclusions. Individuals immunised with YF vaccine 17 D could not be protected against YF: up to 31% children and 10 % adults. Dengue antibodies inhibited YF virus and its significance in terms of YF protection must be investigated.
Referencias
Monath T. Yellow fever: an update. Lancet Infect Dis. 2001;1:11-20.
World Health Organization. Yellow fever situation in Africa en South America. Weekly epidemiological record 2006;81;317-324.
Burke D, Monath T. Flavivirus. En: Knipe D, Howley P, Griffin D, Lamb R, Martin M, Roizman B, Straus S, eds. Fields Virology. Fourth edition. Philadelphia: Lippincott Williams and Wilkins; 2001. pp 1043-1126.
Price W, Thind I. Protection against West Nile virus induced by a previous injection with dengue virus. Am J Epidemiol. 1971; 94:596-606.
Bond J, Hammon W. Epidemiological studies of possible cross-protection between dengue and St. Louis encephalitis arboviruses in Florida. Am J Epidemiol 1970;92:321-330.
Xiao S-Y, Guzman H, Travassos da Rosa A, Zhu H-B, Tesh R. Alteration of clinical outcome and histopathology of yellow fever virus infection in a hamster model by previous infection with heterologous flaviviruses. Am J Trop Med Hyg. 2003; 68:695-703.
Theiler M, Anderson C. The relative resistance of dengue-immune monkeys to yellow fever virus. Am J Trop Med Hyg. 1975; 24:115-117.
Theiler M, Smith H. The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 1937; 65:787-800.
World Health Organization. Standards for the manufacture and control of yellow fever vaccine. United Nations Relief and Rehabilitation Administration. World Health Organ Epidemiol Bull.1945; I:1-365.
Groot H. Sesenta años de vacuna antiamarílica. Biomédica 1999;19:269-271.
Monath T. Yellow fever vaccine. Expert Rev Vaccines 2005;4:553-574.
Belmusto-Worn V, Sanchez J, McCarthy K, Nichols R, Bautista C, Magill A, et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg 2005;72:189-197.
Tavares-Neto J, Freitas-Carvalho J, Teixeira M, Rocha G, Guerreiro S, Damasceno E, et al. Pesquisa de anticorpos contra arbovírus e o vírus vacinal da febre amarela em uma amostra da população de Rio Branco, antes e três meses após a vacina 17D. Rev Soc Bra Med Trop. 2004; 37:1-6.
Guerra H, Sardinha T, da Rosa A, Lima e Costa M. Effectiveness of the yellow fever vaccine 17D: an epidemiologic evaluation in health services. Rev Panam Salud Publica 1997;2:115-120.
Lopes O, Guimaraes S, Carvalho R. Studies on yellow fever vaccine. III-Dose response in volunteers. J Biol Stand. 1988;16:77-82.
Aguirre C. Fiebre Amarilla. Revista Médica de Bogotá1904; 285:198-208.
Peña A, Serpa R, Bevier G. Yellow fever in Colombia with special reference to epidemic in Socorro in 1920. J Prev Med. 1930:4; 417- 457.
Velandia M. Fiebre Amarilla y su control. Biomédica. 2004; 24:5-6.
Derecho a la salud: Evolución de algunos indicadores de interés en salud pública. [Internet]. Disponible en: http://www.minproteccionsocial.gov.co/vbecontent/library/documents /DocNews No15417DocumentNo2666.PDF. Consultado 10/03/2007.
Groot H, Gast A. Observaciones sobre la vacuna de virus 17D contra fiebre amarilla aplicada por escarificación cutánea. Rev Invest (Guadalajara). 1965; 5:5-25.
Ocazionez R, Cortés F, Gómez S. Serotipo, Patrón de infección y dengue hemorrágico en área endémica colombiana. Rev Salud Publica (Bogotá). 2007; 9:262-274.
Ocazionez R, Cortés F, Villar L, Gómez S. Temporal distribution of dengue virus serotypes in Colombian endemic area and dengue incidence. Re-introduction of dengue-3 associated to mild febrile illness and primary infection. Mem Inst Oswaldo Cruz 2006; 101:725-731.
Niedrig M, Laderman M, Emmerich P, Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemaglutination inhibition test, immunofluorescence assay and ELISA. Trop Inf Int Health 1999; 4:867-871.
Monath T, Nichols R, Archambault W, Moore L, Marchesani R, Tian J, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.Am J Trop Med Hyg. 2002;66:533-541.
Fox J, Cabral A. The duration of immunity following vaccination with the 17D strain of yellow fever virus. Am J Hyg. 1943;37:93-120.
Groot H, Kerr JA, Sanmartin CV. Antibodies to yellow fever and other arthropod-borne viruses in human residents of San Vicente de Chucuri, Santander, Colombia. Am J Trop Med Hyg. 1959;8:175-189.
Rosenzweig E, Babione R, Wisseman J. Immnunological studies with group B arthropod-borne viruses, IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. Am J Trop Med Hyg. 1963;12:230-235.
Smithburn K, Mahaffy A. Immunization against yellow fever: studies on time of development and duration of induced immunity. Am J Top Med 1945;25:217-223.
Poland J, Calisher C, Monath T, Downs W, Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull WHO 1981; 59:895-900.
Groot H, Ribero R. Neutralizing and haemaglutination-inhibition antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull WHO 1962;27: 699-707.
Querec T, Pulendran B. Understanding the role of innate immunity in the mechanism of action of the live attenuated Yellow Fever Vaccine 17D. Adv Exp Med Biol.. 2007; 590:43-53.
Barba-Spaeth G, Longman R, Albert M, Rice C. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med. 2005; 202:1179-1184.
Santos A, Bertho A, Dias D, Santos J, Marcovistz R. Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus.Mem Inst Oswaldo Cruz 2005;100:331-337.
Calisher C, Karabatsos N, Darlymple J, Shope R, Porterfield J, Westaway E, et al. Antigenic relationship between Flavivirus as determined by cross-neutralization test with polyclonal antisera. J Gen Virol. 1989;70:37-43.
Gómez S, Ocazionez R. Neutralización del virus de la fiebre amarilla por anticuerpos anti-dengue como factor que puede contribuir a la ausencia de casos urbanos. Biomédica. XIII Congreso Colombiano de Parasitología y Medicina Tropical. 2007;27(2):158
Monath T, Craven R, Adjukiewicz A, Germain M, Francy D, Ferrara L, et al. Yellow fever in the Gambia, 1978-1979: epidemiologic aspect with observations on the occurrence of Orungo virus infections. Am J Trop Med Hyg. 1980:29;912-928.
Ashcroft M. Historical evidence of resistance to yellow fever acquired by residence in India. Trans R Soc Trop Med Hyg.1979; 73: 247-248.
Cómo citar
APA
ACM
ACS
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver
Descargar cita
Visitas a la página del resumen del artículo
Descargas
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Esta revista provee acceso libre inmediato a su contenido bajo el principio de que hacer disponible gratuitamente investigación al publico apoya a un mayor intercambio de conocimiento global.
Todos los contenidos de esta revista, excepto dónde está identificado, están publicados bajo una Licencia Creative Commons Atribución 4.0.
